We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VRT:NYSEVertiv Holdings, LLC Analysis

Data as of 2026-05-28 - not real-time

$319.78

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Vertiv (VRT) is trading at $319.78, well above its DCF‑derived fair value of $182, yielding an implied overvaluation despite a forward PE of 36 versus an industry average of 30. The stock’s price sits above the 20‑day SMA (≈$340) but below the 50‑day SMA (≈$305) and is approaching a key support zone near $300, while the MACD histogram remains negative, indicating short‑term bearish momentum. Nevertheless, the 30‑day volatility of roughly 59 % and a beta of 2.46 point to a highly reactive price profile. On the fundamentals side, revenue grew 30 % YoY, gross margin sits at 37 %, and ROE exceeds 45 %, underscoring strong profitability.
Recent headlines highlight Vertiv’s acquisition of Strategic Thermal Labs, bolstering its AI‑infrastructure cooling capabilities, and a chorus of analysts labeling the stock a “strong‑buy” with a median target near $378, suggesting upside potential if the market re‑prices the growth story. The dividend, though modest at 0.08 % with a 5 % payout ratio, is supported by robust operating cash flow and a low debt‑to‑equity profile. Given the blend of high growth drivers, elevated valuation, and pronounced market risk, the recommendation leans toward a cautious hold in the near term, with a more bullish stance for medium‑term investors who can tolerate volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support around $300
  • negative MACD histogram
  • high short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • 30 % YoY revenue growth
  • Strategic Thermal Labs acquisition expanding AI cooling portfolio
  • analyst median target near $378 indicating upside

Long Term

> 3 years
Neutral
Model confidence: 8/10

Key Factors

  • strong ROE and cash flow generation
  • sustainable dividend despite low yield
  • global infrastructure demand supporting long‑term demand

Key Metrics & Analysis

Financial Health

Revenue Growth30.10%
Profit Margin14.37%
P/E Ratio80.3
ROE45.10%
ROA11.15%
Debt/Equity76.91
P/B Ratio31.0
Op. Cash Flow$2.6B
Free Cash Flow$2.0B
Industry P/E30.1

Technical Analysis

TrendBullish
RSI46.8
Support$299.80
Resistance$379.93
MA 20$339.93
MA 50$305.43
MA 200$209.55
MACDBearish
VolumeStable
Fear & Greed Index92.34

Valuation

Fair Value$181.92
Target Price$377.21
Upside/Downside17.96%
GradeOvervalued
TypeGrowth
Dividend Yield0.08%

Risk Assessment

Beta2.46
Volatility59.38%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.